IH

Imran Hanif Khanda

Director Designated Partner DIN 07496396
DIN 07496396 First appointment May 2016 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since May 2016
Shareholding value β€’β€’β€’β€’ Premium profile

About Imran Hanif Khanda

Data last updated:

Imran Hanif Khanda was a Designated Partner at Icon Pharmaceuticals Llp (2021) and Director at 23 Shoppe Limited (from 2016). The companies operate in Chemicals.

DIN 07496396
Primary Designation Designated Partner
Industry Chemicals
First Appointment 24 May 2016
Oldest Company Age 10 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner18 Jun 20212021Under Process Of Striking Off
23 Shoppe Limited U51909GJ2016PLC092143
Director24 May 20162016Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
23 Shoppe Limited
Icon Pharmaceuticals Llp
Premium access

Shareholding and investment profile for Imran Hanif Khanda

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Imran Hanif Khanda

Imran Hanif Khanda was first appointed on 24 May 2016 as Director at 23 Shoppe Limited. The most recent appointment on record is 18 Jun 2021 at Icon Pharmaceuticals Llp.

Imran Hanif Khanda held 2 earlier board appointments: Icon Pharmaceuticals Llp (Designated Partner, 18 Jun 2021 to 04 Dec 2021); 23 Shoppe Limited (Director, from 24 May 2016).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available